Capital World Investors’s Centessa Pharmaceuticals CNTA Stock Holding History

Capital World Investors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,832,548	Closed	-$192M	–	647
2026 Q1	$192M	Buy	4,832,548 +3,673,849	+317%	+$94M	0.03%	313
2025 Q4	$29M	Buy	1,158,699 +473,894	+69%	+$12M	﹤0.01%	462
2025 Q3	$16.6M	Buy	684,805 +267,982	+64%	+$4.76M	﹤0.01%	486
2025 Q2	$5.48M	Buy	+416,823	New	+$5.28M	﹤0.01%	514

Capital World Investors's CNTA Position: Q2 2026 in Review

Capital World Investors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 4,832,548 shares — an estimated $192M sold.

Capital World Investors first reported a position in CNTA in Q2 2025 and held it in 4 quarters. The position peaked at $192M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Capital World Investors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Capital World Investors sold 4,832,548 Centessa Pharmaceuticals shares in Q2 2026, an estimated $192M.
Capital World Investors first reported a position in Centessa Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Capital World Investors's Centessa Pharmaceuticals position peaked at $192M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.